Solutions
Advisory Services
Clinical Development
- Generics Development
- Clinical Operations
- Clinical Data Sciences
- Medical and Safety Services
- RWD & RWE Services
Post Marketing
- Safety Services
- Post marketing Studies
- Regulatory Affairs
Are you ready to lead the next wave of transformation in life sciences? Across Navitas’ industry-leading networks, pvnet®, pvconnect®, labelnet™, and more, over 100+ member companies are rewriting the playbook for 2026. Here’s what’s setting the pace for the industry’s boldest innovators: 1. Technology &...
New “Ask Your Biostatistician” Video Clinical trials generate data from dozens of sources, EDC systems, laboratories, imaging vendors, safety platforms, wearables and ePRO devices. Ensuring all of it aligns is essential for clinical trial data quality, trustworthy analyses and regulatory submission readiness. This ongoing discipline, ...
Pharma’s digital maturity has accelerated recently, and emerging technologies are core enablers of faster R&D. As we move into 2026, five digital technologies stand out as the most transformative in the biopharma industry. 1. Big Data Platforms & Intelligence-Driven RWE Ecosystems Modern R&D relies on the seamless flow of clinica...
PV India 2025 once again proved why it remains one of the most sought-after pharmacovigilance peer networks, bringing together senior drug safety leaders for deep, high-quality discussions and future-ready insights. As one of the most established PV peer networks in India, the forum continues to be recognized for its ability to encourage quality di...
On this World Diabetes Day, we reaffirm our global commitment to reducing the burden of diabetes. Because it embodies the science behind better diabetes care, the euglycemic clamp study stands as one of the most significant innovations in modern diabetes research. The euglycemic clamp is a symbol of precision and by offering an accurate measure of ...
Be First-to-Market with Our Bioavailability & Bioequivalence (BABE) CRO Services Bioavailability (BA) and Bioequivalence (BE) studies are critical components in developing or marketing a generic drug. To secure approval from global health authorities such as the US FDA, pharmaceutical companies must conduct a bioequivalence study comparing thei...
Navitas Life Sciences’ medical information contact center (MICC) services help global clients achieve operational excellence, ensure compliance and enhance customer satisfaction while significantly reducing costs. Our proven approach recently enabled a leading global pharmaceutical company to achieve a 30% cost reduction through an integrate...
Insights from the PHUSE Chennai SDE Navitas Life Sciences was proud to be part of the highly attended PHUSE India SDE in Chennai, sharing our expertise in biostatistics, data sciences, and regulatory submissions. We were recognized as a Major Contender in the Everest Group Clinical Data Management Operations PEAK Matrix® Assessment 2025, which...
The pharmaceutical industry is at a turning point in how it manages regulatory submissions. Agencies across the world, from the U.S. Food and Drug Administration (FDA) to the European Medicines Agency (EMA), are demanding structured and timely submissions. Companies that continue relying on legacy publishing systems risk operational bottlenecks, co...
Real World Evidence Market size The healthcare and pharmaceutical landscape is changing at an unprecedented pace. Traditional randomized controlled trials (RCTs), while the gold standard, are not always enough to answer today’s complex clinical questions. This is where real world evidence (RWE), generated from real world data (RWD) such as p...